Kronos Bio Inc. (KRON)
NASDAQ (CM) NASDAQ (CM) Primary Summary
KRON Chart
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRON
NEW YORK , May 1, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Kronos Bio, Inc. (NASDAQ: KRON ), relating to the proposed merger with Concentra Biosciences, LLC.
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC ( “Concentra”), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock (“Kronos Bio Common Stock”), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 50% of the net proceeds in the case of a disposition of the Company's product candidates known as KB-9558 and KB-7898 that occurs within 2 years following closing; (ii) 100% of the net proceeds in the case of a disposition of the Company's product candidates known as KB-0742, lanraplenib and entospletinib that occurs prior to closing; (iii) 100% of cost savings realized prior to closing; (iv) 80% of cost savings realized between the merger closing date and the second (2nd) anniversary of the merger closing date; and (v) 50% of cost savings realized between the second (2nd) anniversary of the merger closing date and the third (3rd) anniversary of the merger closing date, each pursuant to the contingent value rights agreement (the “CVR Agreement”).
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results.
Kronos Bio Inc. (KRON) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kronos Bio Inc. ever had a stock split?
Kronos Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Deborah A. Knobelman Ph.D. CEO | NASDAQ (CM) Exchange | 50107A104 Cusip |
| US Country | 8 Employees | - Last Dividend | - Last Split | 9 Oct 2020 IPO Date |
Overview
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company that has set its sights on the ambitious goal of discovering and developing innovative therapeutics aimed at treating a wide range of cancers as well as other serious diseases. Founded in 2017, the company has swiftly positioned itself within the dynamic landscape of the healthcare sector in the United States. Based in San Mateo, California, Kronos Bio leverages cutting-edge research and development strategies to tackle some of the most challenging diseases facing patients today.
Products and Services
The company's pipeline of lead product candidates includes:
- KB-0742:
An oral cyclin dependent kinase 9 inhibitor that has reached Phase 2 clinical trials. This promising candidate is specifically designed for the treatment of MYC-amplified solid tumors, showcasing Kronos Bio's focused approach in targeting cancer's molecular drivers.
- KB-9558:
A transformative approach towards treating multiple myeloma, focusing on a core oncogenic transcription factor integral to the disease. This indicates Kronos Bio's commitment to addressing hard-to-treat cancers by targeting their fundamental biological mechanisms.
Contact Information
